Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2017
At a glance
- Drugs PF 4518600 (Primary) ; Axitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Jul 2017 Planned End Date changed from 10 Sep 2021 to 19 Jul 2021.
- 20 Jul 2017 Planned primary completion date changed from 10 Sep 2020 to 19 Jul 2020.